logo
China's Tianwen-2 mission launches to explore asteroid that may be a lunar fragment

China's Tianwen-2 mission launches to explore asteroid that may be a lunar fragment

Yahoo2 days ago

Sign up for CNN's Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more.
China has launched an ambitious mission to study two intriguing objects in our solar system, the likes of which have never been visited by a spacecraft before.
The Tianwen-2 mission launched aboard a Long March 3B rocket from the Xichang Satellite Launch Center in Sichuan province at 1:31 p.m. ET on Wednesday (1:31 a.m. Thursday local time in China), according to the China National Space Administration.
Like Tianwen-1, which lifted off in July 2020 with two aims — delivering an orbiter and a rover to Mars — Tianwen-2 has two goals.
The mission's initial goal is to fly by and collect the country's first samples from an asteroid. The space rock, called Kamoʻoalewa or asteroid 2016 HO3, may be a chunk chipped off the moon, which has become a 'quasi-satellite' near our planet. The spacecraft will spend one year flying to the asteroid and another year orbiting and assessing potential landing sites.
After dropping off those samples at Earth via a capsule about 2 ½ years from now, the mission will then take seven years to reach an unusual object called main belt comet 311P/Pan-STARRS and conduct a flyby. Sometimes referred to as an active asteroid, the celestial object orbits between Mars and Jupiter and produces dusty, comet-like tails.
Both Kamoʻoalewa and 311P/Pan-STARRS are incredibly interesting targets that stem from populations of objects that, up until a couple of years ago, astronomers barely knew existed, said Dr. Teddy Kareta, a postdoctoral associate of planetary science at Lowell Observatory in Flagstaff, Arizona.
'Now we get to study them up close in a kind of detail that will really revolutionize our understanding of them and objects like them,' Kareta said in an email. 'Plus, any time we see a new kind of Solar System object for the first time with a spacecraft … it's like opening presents on your birthday. Whatever's underneath the wrapping paper, it's always exciting to see something for the first time and to try to do your best to understand it.'
Astronomers first discovered Kamoʻoalewa in 2016 using the Panoramic Survey Telescope and Rapid Response System, or Pan-STARRS, telescope in Hawaii. Ben Sharkey, now a visiting senior faculty specialist at the University of Maryland, College Park, led a study published in November 2021 suggesting that the Ferris wheel-size asteroid may be a massive boulder ejected from the moon by an impact.
The name Kamoʻoalewa comes from a Hawaiian creation chant that alludes to an offspring traveling on its own.
It will be the smallest asteroid ever visited, measuring between 150 and 190 feet (46 and 58 meters) in diameter, said Dr. Patrick Michel, director of research exceptional class at the French National Centre for Scientific Research. Michel also served as a coinvestigator on missions by NASA and the Japan Aerospace Exploration Agency — OSIRIS-REx and Hayabusa2, respectively — that returned asteroid samples to Earth. Bennu, the asteroid sampled by OSIRIS-REx, had a diameter similar to the height of the Empire State Building, or 1,614 feet (492 meters).
Kamoʻoalewa is a quasi-satellite, a type of near-Earth asteroid that orbits the sun but sticks close to Earth, coming within about 9 million miles (14.5 million kilometers) of our planet.
'Until Ben Sharkey … saw that it reflected light like the Moon, we didn't think there were chunks of the Moon out in near-Earth space,' Kareta said. 'The Moon's covered in craters, but who knew that the violent formation of those craters might toss tennis court sized rocks seemingly intact that we could find and study thousands or millions of years later?'
Studying and sampling Kamoʻoalewa could help astronomers determine whether the space rock actually originated from the moon or if it just reflects light similarly, Kareta said. Kareta is also involved with a study led by Sharkey that will use the James Webb Space Telescope to study Kamoʻoalewa in more detail next year.
'If it's actually from the Moon, then we might be able to identify other lunar samples that have similar properties and help to get an idea of where it came from on the lunar surface,' Kareta said. 'If it just looks like the Moon but is actually from somewhere else, the sample will facilitate a radically more informed search for where Kamoʻoalewa actually came from.'
The mission could also shed light on asteroids that can cause damage if they were to strike Earth. Kamoʻoalewa is comparable in size to the object that devastated Tunguska in Siberia over a century ago, Michel said.
A roughly 98-foot-wide (30-meter-wide) asteroid struck the Podkamennaya Tunguska River in a remote Siberian forest of Russia in 1908, according to The Planetary Society. The event leveled trees and destroyed forests across 830 square miles (2,150 square kilometers).
Orbiting and landing on such a small body is complicated, which is part of what makes the mission both interesting and risky, Michel said.
'To get into orbit, you really have to get very close, and even if you just follow it, the maneuvers remain very sensitive, because there's really very little gravity and its rapid rotation forgives no mistakes,' Michel said. 'Plus, the plan is to get a sample, so there are not many areas where the probe can land safely.'
The space rock 311P/Pan-STARRS is one of the best-studied active asteroids, Kareta said.
'Even just (25) years ago, we didn't know there were active asteroids at all — scientists thought that only icy comets from the outer Solar System could produce comet-like tails, but it turns out that a couple of dozen asteroids do so as well without much or any ice involved,' Kareta said.
Astronomers have come up with a number of hypotheses for why the object is throwing off dust, including posing the existence of pressure pockets that eject material and the idea that other objects could be impacting 311P/Pan-STARRS and releasing elements, Michel said.
Flying by the active asteroid could show exactly what processes are creating the dusty tails streaming from the object and might reveal possibilities scientists haven't even considered, Kareta said.
'This will be the first time such an object is observed up close and we can determine which mechanism (there may be others) drives the activity,' Michel said.
The data gathered by Tianwen-2 could enhance a wide range of studies of objects within the inner solar system, which includes Mercury, Venus, Earth, Mars and the asteroid belt, Kareta said.
'There's a tremendous amount we don't know about either object,' Kareta said. 'I don't think any spacecraft has ever gotten to its target and not found at least a few big surprises — I'm sure some of our current understanding for either object is completely wrong, and I'm excited to see how.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China launches Tianwen-2 to chase Moon-origin asteroid, explore hybrid comet
China launches Tianwen-2 to chase Moon-origin asteroid, explore hybrid comet

Yahoo

timean hour ago

  • Yahoo

China launches Tianwen-2 to chase Moon-origin asteroid, explore hybrid comet

China has launched its most ambitious deep space mission yet. On Wednesday, the Tianwen-2 probe lifted off atop a Long March 3B rocket at 1:31 pm Eastern (17:31 UTC) from the Xichang Satellite Launch Center in Sichuan province. The mission aims to collect samples from a near-Earth asteroid and later survey a comet in the main asteroid belt, marking the country's first asteroid sampling effort. Tianwen-2 is now en route to asteroid 469219 Kamoʻoalewa (2016 HO3), a small rocky body orbiting close to Earth. The probe is expected to reach the asteroid in mid-2026 and return samples to Earth in 2027. After the sample return, it will continue its journey toward comet 311P/PANSTARRS, with arrival expected around 2035. The China Aerospace Science and Technology Corporation (CASC) confirmed the successful launch just over an hour after liftoff. Xinhua reported that 'the spacecraft unfolded its solar panels smoothly,' and the China National Space Administration (CNSA) officially declared the mission a success. Discovered in 2016 by researchers in Hawaii, Kamoʻoalewa is believed to be a fragment of the Moon. Scientists hope to analyze its structure, mineral content, and origin. It is roughly 40 to 100 meters in diameter. Depending on surface conditions, the mission will employ three sampling methods — hover sampling, touch-and-go, and anchored drilling. Tianwen-2 will then use Earth's gravity to redirect itself toward comet 311P. The comet orbits between Mars and Jupiter and displays asteroid-like behavior, making it ideal for studying transitional objects in the solar system. Reaching and sampling small celestial bodies is more challenging than orbiting planets. The mission must navigate weak and irregular gravity fields, which rule out traditional orbiting methods. 'These bodies have extremely weak and irregular gravity fields,' Franco Perez-Lissi, Ramses mission systems engineer at the European Space Agency (ESA), told SpaceNews. 'So we cannot rely on traditional orbiting like we do around the planet.' Tianwen-2 must closely match the asteroid's rotation and speed for successful sampling. Perez-Lissi likened the maneuver to 'trying to dock a boat with a mountain floating in space and tumbling really unpredictably and with almost no gravity.' The probe carries 11 science payloads, including spectrometers, high-resolution cameras, a radar sounder, and particle detectors. These will study the composition, geological features, magnetic fields, and solar wind interactions at both the asteroid and the comet. Past missions like NASA's OSIRIS-REx and JAXA's Hayabusa2 have returned organic materials, including amino acids and nucleobases—key building blocks of life. Tianwen-2 follows the successful Tianwen-1 Mars mission and precedes plans for Mars sample return and Jupiter system exploration. These missions are part of a long-term roadmap that includes the International Lunar Research Station and a Venus sample return. According to Xinhua, Shan Zhongde, head of the CNSA, 'expressed his expectation of yielding groundbreaking discoveries and expanding humanity's knowledge of the cosmos.' China continues to invest heavily in space, with its Tiangong space station now operational and a crewed Moon mission planned for later this decade. Tianwen-2 could mark another leap forward in China's 'space dream,' as articulated by President Xi Jinping.

Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Yahoo

time2 hours ago

  • Yahoo

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

WALTHAM, Mass., May 30, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference (New York, NY): Presentation on Wednesday, June 4, at 7:35am ET Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Miami, FL): Presentation on Monday, June 9, 2025 at 8:40am ET A live webcast of each presentation can be accessed under "Events and Presentations" on the Investors section of the Viridian website at A replay of the webcasts will be available following the completion of the event. About Viridian Therapeutics Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is based in Waltham, Massachusetts. For more information, please visit Follow Viridian on LinkedIn and X. View source version on Contacts IR@ Media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Business Wire

time2 hours ago

  • Business Wire

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference (New York, NY): Presentation on Wednesday, June 4, at 7:35am ET Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Miami, FL): Presentation on Monday, June 9, 2025 at 8:40am ET A live webcast of each presentation can be accessed under 'Events and Presentations' on the Investors section of the Viridian website at A replay of the webcasts will be available following the completion of the event. About Viridian Therapeutics Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is based in Waltham, Massachusetts. For more information, please visit Follow Viridian on LinkedIn and X.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store